Company news
Bergs Securities recruits Jonathan Hedin to its Corporate Finance team
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Corporate Finance
Bergs Securities acted as sole global coordinator and sole bookrunner in the fully guaranteed SEK 46m rights issue and the SEK 42m private placement of convertible bonds in Abliva
Abliva develops medicines for the treatment of mitochondrial disease. This congenital, rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The portfolio includes projects at different stages and ranges from early discovery phase to clinical phase.
Related News
Certified Adviser
Bergs Securities is proud to have acted as certified adviser and financial advisor to AIRA in its application to list its shares on Nasdaq First North Growth Market.
Corporate Finance
Bergs Securities acted as financial adviser and sole bookrunner to Medclair in its SEK 23 million directed share issue to Eiffel Investment Group